Virtually all cases of cervical cancer are caused by a persistent infection involving human papillomaviruses (HPV). Yet not every HPV type carries the same risk for the development of cervical cancer. The new PapilloCheck high-risk test focuses on parallel analysis of 14 HPV types of the highrisk group (hrHPV) that are recognised as carcinogenic.

In a recent clinical study, the test system based on microarray technology showed a clinically relevant sensitivity of 95.8 per cent and a clinical specificity of 96.7 per cent for the detection of high-grade precancerous lesions, thus meeting key requirements for fast and clear results in cervical cancer screening. PapilloCheck high-risk helps doctors assess patients' risk of cancer more effectively. The costs for the PapilloCheck high-risk HPV test are covered by statutory health insurers if a smear test is inconclusive, i.e. with a Pap result of Class 3 or above.

PapilloCheck® high-risk is part of the oCheck® product line from Greiner Bio-One GmbH.

For further information please visit www.greinerbioone.com

Greiner Bio-One is specialised in the development, production and distribution of plastic laboratory equipment. The company is technology partner for universities, research institutes and the diagnostic, pharmaceutical and biotechnology industries as well. With the BioScience division, Greiner Bio-One ranks among the leading providers of specialised products for the cultivation and analysis of cell and tissue cultures, as well as microplates for high-throughput screening, allowing industry and research most rapid and efficient drug screening. Additionally Greiner Bio-One develops innovative biochip technologies for genotyping. Under the management of Heinz Schmid, the German headquarters of the BioScience division in Frickenhausen (Baden-Württemberg) controls the whole research and development activities in the product ranges Cell Culture, High-Throughput Screening, Biochips and OEM.

Greiner Bio-One GmbH is a division of Greiner Bio-One International AG, based in Kremsmuenster (Austria). Today Greiner Bio-One International AG generates a turnover of 278.6 million Euro. It has over 1,400 employees and operates globally with 19 own subsidiaries and numerous distributors in more than 100 countries.